Endocrinologists in Boston have identified a key enzyme in the synthesis of lipids called FAHFAs that have beneficial effects on insulin sensitivity, blood sugar control and other metabolic-related parameters in humans and mice. The discovery, reported recently in Nature, opens the door to potential new treatments for Types 1 and 2 diabetes. 

“The long-term goal is to safely replace insulin-producing pancreatic beta cells in people with Type 1 diabetes, but this would require a way to protect those cells from attack by the immune system,” says Barbara B. Kahn, MD, who is vice chair for research strategy in the Department of Medicine at Beth Israel Deaconess Medical Center (BIDMC). “We have shown that these FAHFA lipids protect beta cells from immune attack and metabolic stress. If we could increase FAHFA levels, we think this could be beneficial for both Type 1 and Type 2 diabetes.”

Search Antibodies
Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.

In 2014, Kahn’s lab in collaboration with Alan Saghatelian, now a professor at the Salk Institute, discovered the previously unknown class of lipids, which they named Fatty Acid Esters of Hydroxy Fatty Acids, or FAHFAs. In humans, FAHFA levels are linked with sensitivity to insulin. FAHFAs improve blood sugar control in obese, diabetic mice, a model of Type 2 diabetes, and they reduce proinflammatory immune responses which results in a lower incidence of Type 1 diabetes in mice.

FAHFAs also protect the cells in humans that make insulin, known as pancreatic islet beta cells, from attack by immune cells and from cellular stress. In addition, levels of these lipids are low in the serum and fat tissue of people who are at risk for, or who have, Type 2 diabetes.

In the current study, Kahn’s lab in collaboration with Saghatelian determined that an enzyme called adipose triglyceride lipase (ATGL) plays a key role synthesizing FAHFA lipids. The experiments, carried out in mice and in human and mouse cells, showed that ATGL is the major biosynthetic enzyme for FAHFAs in fat tissues.

Further work will investigate whether ATGL is also the major biosynthetic enzymes in other tissues and whether additional enzymes help synthesize the beneficial lipids. The discovery could ultimately pave the road to new therapeutic strategies for people with diabetes.

Because humans who are both obese and resistant to insulin have lower ATGL levels in white adipose tissue compared to lean people or people who are both obese and insulin-sensitive, scientists suspect that ATGL may contribute to the reduction in FAHFAs in insulin-resistant people and hence to the risk for, or severity of, Type 2 diabetes.

“Ideally, the new findings might be used to boost the levels of FAHFAs in people at risk for Type 2 diabetes to prevent it, or to improve blood glucose control in people who already have Type 2 diabetes,” said Kahn, who is also the Minot Professor of Medicine at Harvard Medical School. “Additionally, these new findings might be used to increase FAHFA levels in people at risk for Type 1 diabetes to prevent it—as we did in mice. Understanding the regulation of ATGL could lead to strategies to increase these beneficial lipids in metabolic and immune-mediated diseases.”